Loading...
Market
Will IDEAYA complete Phase 1 trials of SHR-4849 by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
IDEAYA Biosciences official announcements or clinical trial registries
Story
IDEAYA Biosciences Licenses SHR-4849 from Hengrui Pharma for $75M, Total Payments Around $1B, Targeting SCLC and NET Tumors
Dec 29, 2024, 11:02 AM
IDEAYA Biosciences has entered into an exclusive licensing agreement with Hengrui Pharma for SHR-4849, a novel drug currently in Phase 1 development. This drug is a DLL3 Topo-I-Payload antibody-drug conjugate (ADC) targeting small cell lung cancer (SCLC) and neuroendocrine tumors (NET). The licensing deal is valued at approximately $75 million, with potential total payments reaching around $1 billion. This move reflects a growing trend where biotechnology companies are increasingly sourcing innovation from China, highlighting the shifting dynamics in the pharmaceutical landscape.
View original story
Similar markets
No • 50%
Yes • 50%
Negative efficacy, but good safety • 25%
Positive efficacy, but safety concerns • 25%
Positive efficacy and safety results • 25%
Negative efficacy and safety concerns • 25%
Worsening condition • 25%
Moderate improvement • 25%
Significant improvement • 25%
No improvement • 25%
Mixed results • 25%
Trial discontinued • 25%
Negative results • 25%
Positive results with MRD-negative CR • 25%
Significant improvement • 25%
No improvement • 25%
Moderate improvement • 25%
Worse outcomes • 25%
No • 50%
Yes • 50%
